News

Filter

1 to 9 of 75 results

Tau-based vaccines could transform early Alzheimer’s treatment, says analyst

Tau-based vaccines could transform early Alzheimer’s treatment, says analyst

27-01-2015

While current treatments for Alzheimer’s disease are only able to ease symptoms temporarily, tau-based…

AC ImmuneBiotechnologycrenezumabEli LillygantenerumabJohnson & JohnsonMarkets & MarketingNeurologicalResearchRochesolanezumabVaccines

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan

01-12-2014

Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Medivation and Astellas' Xtandi to be market-leader in prostate cancer by 2023

Medivation and Astellas' Xtandi to be market-leader in prostate cancer by 2023

31-10-2014

Xtandi (enzalutamide), produced by biopharma company Medivation and Japanese drug major Astellas Pharma…

AstellasDecision Resources GroupJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Vertex to drop hep C drug Incivek following poor sales

14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals has said it will cease marketing its hepatitis C treatment…

Anti-viralsBiotechnologyGilead SciencesHepatitis C treatmentIncivekJohnson & JohnsonMarkets & MarketingSovaldiTelaprevirUSAVertex Pharmaceuticals

Global epileptic anticonvulsants market - 2014-2020

Global epileptic anticonvulsants market - 2014-2020

16-07-2014

North America dominates the global epileptic anticonvulsants market and is followed by Europe, according…

Abbott LaboratoriesAsia PacificBusiness FinanceEpilepsyGlaxoSmithKlineGlobalHealth Medical PharmaHealth Medical PharmaJohnson & JohnsonMarkets & MarketingNeurologicalNovartisPfizerPharmaceuticalUCB

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

1 to 9 of 75 results

COMPANY SPOTLIGHT

Menarini

Back to top